...

首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >AN INDIRECT COMPARISON BETWEEN ADALIMUMAB, BARICITINIB AND TOFACITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

【24h】

AN INDIRECT COMPARISON BETWEEN ADALIMUMAB, BARICITINIB AND TOFACITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

机译：阿达木单抗，巴立替尼和托法替尼治疗类风湿关节炎的间接比较

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2016年第7期|共1页
作者
Migliore A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. AN INDIRECT COMPARISON BETWEEN ADALIMUMAB, BARICITINIB AND TOFACITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS [J] . Migliore A. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：阿达木单抗，巴立替尼和托法替尼治疗类风湿关节炎的间接比较
2. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain [J] . Max Schlueter, Elaine Finn, Silvia Díaz, ClinicoEconomics and Outcomes Research . 2019,第6期

机译：Baricitinib与adalimumab在西班牙治疗中度至重度类风湿关节炎的成本效益分析
3. Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy: [J] . Roberto Ravasio, Silvia Antonelli, Veronica Rogai, Global & Regional Health Technology Assessment . 2018,第1期

机译：在意大利治疗类风湿关节炎所需的巴立替尼和阿达木单抗治疗所需的平均费用：
4. IL1B T-31C and VEGFA C+936T SNPs may be used as prognostic markers of rheumatoid arthritis treatment inefficiency [C] . Vitaly Omelchenko, Elena Letyagina, Alla Shevchenko, Conference on Cognitive Sciences, Genomics and Bioinformatics . 2020

机译：IL1B T-31C和VEGFA C + 936T SNP可用作类风湿关节炎治疗效率低下的预后指标
5. Comparison of the Therapeutic Efficacy of Rheumatoid Arthritis Treatments [D] . Davis, Kacy. 2021

机译：类风湿性关节炎治疗治疗疗效的比较
6. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison [O] . B Fautrel, B Zhu, P C Taylor, 2020

机译：对幼稚性关节炎患者的痛苦痛和毒素和Tofacitinib的痛苦和物理功能改善的比较有效性与生物学或常规的合成疾病改性抗胃酸药物治疗的类风湿性关节炎患者：匹配调整后的间接比较
7. SAT0225 Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC) [O] . B. Fautrel, B. Zhu, P. C. Taylor, 2018

机译：SAT0225在CSDMARD-NAINGVAVINALIN关节炎患者中对痛苦痛苦和HAQ-DI改善的比较有效性和HAQ-DI改善，TOCOLIZUAB和TOFACITINIB单药治疗患者：匹配调整的间接比较（MAIC）

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号